• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Grove Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

    11/3/22 4:45:34 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRVI alert in real time by email
    upxi_8k.htm
    0001775194false00017751942022-10-312022-10-31iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    _________________

     

    FORM 8-K

     

    _________________

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) 

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported):  October 31, 2022

     

    UPEXI, INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada

     

    333-25526

     

    83-3378978

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    17129 US Hwy 19 N.

    Clearwater, FL 33760

    (Address of Principal Executive Offices) (Zip Code)

     

    (701) 353-5425

    (Registrant's telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    _______________________________

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.001

     

    UPXI

     

    NASDAQ

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On October 31, 2022 (the “Closing Date”), Upexi, Inc. (the “Company”) and its wholly owned subsidiary Upexi Enterprise, LLC (the “Buyer”) entered into a Securities Purchase Agreement (the “SPA”) with E-Core Technology, Inc. d/b/a New England Technology, Inc., a Florida corporation (the “Company”), David Romano individually and in his capacity as Seller Representative (“Seller Representative”), Nick Romano (“Nick”), and Eric Limont (“Eric”, and together with Seller Representative and Nick, each a “Seller” and collectively the “Sellers”). Pursuant to terms of the SPA Sellers sold 100% of the stock of the Company to the Buyer (the “Transaction”). The base consideration paid by the Buyer to the Sellers in the transaction totals Twenty-Four Million One Hundred Thousand Dollars ($24,100,000), subject to adjustment, and consists of:

     

    (i) Three Million One Hundred Thousand Dollars ($3,100,000) paid on or before the date that is thirty (30) days after the Closing Date from which Nine Hundred Thousand Dollars ($900,000) of such amount otherwise payable to Nick shall be paid directly to the Company to pay down a promissory note in the amount of One Million Five Hundred Thousand Dollars ($1,500,000) principal amount owed to the Company by Nick;

     

    (ii) One Million Two Hundred Forty-Seven Thousand Four Hundred and Two shares of Parent’s restricted common stock with a value equal to Six Million Dollars ($6,000,000);

     

    (iii) Promissory notes in the total original principal amount of Five Million Seven Hundred Fifty Thousand Dollars ($5,750,000) issued by the Buyer to the Sellers (the “Notes 1”), which Notes 1 shall be payable upon maturity, carry a term of twelve (12) months, at an interest rate of four percent (4.0%), provided, however, the Parties agree that Six Hundred Thousand Dollars ($600,000) of the principal amount of the Notes 1 otherwise payable to Nick shall be satisfied through the cancellation of an equal amount of debt owed by Nick to the Company;

     

    (iv) Promissory notes in the total original principal amount of Five Million Seven Hundred Fifty Thousand Dollars ($5,750,000) issued by the Buyer to the Sellers (the “Notes 2”), which Notes 2 shall be payable upon maturity, carry a term of twenty-four (24) months, at an interest rate of four percent (4.0%); and

     

    (v) Promissory notes in the total original principal amount of Three Million Five Hundred Thousand Dollars ($3,500,000) issued by the Buyer to the Sellers (the “Notes 3”), which Notes 3 shall carry a term of thirty-six (36) months, at an interest rate of zero percent (0.0%). Sellers may convert all, but not less than all, of the Notes 3 into shares of the Buyer’s restricted common stock, by providing notice of conversion to the Buyer on the two (2) year anniversary of the issuance of the Notes 3, at a conversion price equal to Four and 81/100 Dollars ($4.81). If the Sellers do not exercise their conversion right, the principal balance of the Notes 3 will be paid in twelve (12) equal monthly payments commencing on the two (2) year anniversary of the issuance of the Notes 3, provided, however, the amount due at maturity shall be reduced by (i) the percentage by which the Company’s Adjusted EBITDA is less than Three Million Dollars ($3,000,000) during the twelve month period commencing on the Closing Date, plus (ii) the percentage by which the Company’s Adjusted EBITDA is less than Three Million Dollars ($3,000,000) during the twelve months period commencing on the one year anniversary of the Closing Date, plus (iii) the percentage by which the Company’s Adjusted EBITDA is less than Two Million Dollars ($2,000,000) during the twelve months period commencing on the two year anniversary of the Closing Date, up to a maximum aggregate reduction not to exceed the full amount due under Note 3. Notwithstanding the foregoing, in the event the Company’s Adjusted EBITDA for the three (3) year period commencing on the Closing Date exceeds Eight Million Dollars ($8,000,000), then, any reductions in the amounts due under Notes 3 pursuant to the adjustment mechanisms set forth above shall be reversed in full and any such reduced amount(s) shall be promptly paid to the Sellers as additional consideration.

     

     

    2

     

     

    The Transaction provides for a two way post-closing working capital adjustment based on target working capital on the Closing Date of Eight Million Five Hundred Thousand Dollars ($8,500,000).

     

    The assertions embodied in the representations and warranties contained in the SPA were made solely for purposes of the SPA and are not intended to provide factual, business, or financial information about the Company, the Sellers, or the Buyer. Moreover, some of those representations and warranties (i) may not be accurate or complete as of any specified date, (ii) may be subject to a contractual standard of materiality different from those generally applicable to shareholders or different from what a shareholder might view as material, (iii) may have been used for purposes of allocating risk among the Company, the Sellers and the Buyer, rather than establishing matters as facts, or (iv) may have been qualified by certain disclosures not reflected in the SPA that were made to the other party in connection with the negotiation of the SPA and generally were solely for the benefit of the parties to that agreement. The SPA should not be read alone, but should instead be read in conjunction with the other information regarding the Company that has been, is or will be contained in, or incorporated by reference into, documents that the Company files with the SEC.

     

    Item 2.01 Completion of Acquisition or Disposition of Assets.

     

    The Transaction closed on October 31, 2022. The information provided in Item 1.01 of this Current Report on Form 8-K related to the SPA is incorporated by reference into this Item 2.01.

     

    Item 8.01 Other Events.

     

    On November 2, 2022, the Company issued a press release announcing its entry into the SPA and the closing of the Transaction, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

     

    The information in Item 8.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this Report in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit No.

     

    Exhibit Description

    99.1

     

    Press Release issued by Upexi, Inc., dated November 2, 2022.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL Document).

     

     

    3

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    UPEXI, INC.

     

     

     

     

     

    Date: November 3, 2022

    By: 

    /s/ Allan Marshall                                              

     

     

     

    Allan Marshall

     

     

     

    Chief Executive Officer and Chairman

     

     

     

    4

     

    Get the next $GRVI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRVI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GRVI
    SEC Filings

    View All

    Grove Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    12/15/22 4:05:24 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Grove Inc.

    EFFECT - UPEXI, INC. (0001775194) (Filer)

    12/5/22 12:15:12 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Grove Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    12/2/22 9:15:45 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Marshall Allan bought $63,909 worth of shares (17,303 units at $3.69), increasing direct ownership by 0.68% to 2,575,081 units

    4 - UPEXI, INC. (0001775194) (Issuer)

    1/11/23 4:56:21 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Marshall Allan bought $49,320 worth of shares (12,000 units at $4.11), increasing direct ownership by 0.47% to 2,557,778 units

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/13/22 5:48:52 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Marshall Allan bought $73,161 worth of shares (18,475 units at $3.96), increasing direct ownership by 0.73% to 2,545,778 units

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/5/22 3:24:06 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Grove, Inc. Announces Name and Symbol Change to Upexi, Inc. "UPXI"

    HENDERSON, Nev., Aug. 17, 2022 /PRNewswire/ -- Grove Inc. (NASDAQ:GRVI), a market leader in Amazon and eCommerce brand ownership and aggregation, announces that today, August 17, 2022, its trading name on the Nasdaq officially changed from "Grove Inc." to "Upexi, Inc." and its ticker symbol changed from "GRVI" to "UPXI". This accompanies previous press releases notifying investors of this change. CEO Allan Marshall stated, "Last month, we announced our growth strategy in a letter to shareholders that focused on our acquisition plan to bring more, profitable eCommerce brands in various industries under our umbrella. Moving to a new name and stock ticker is a reflection of the progress we have

    8/17/22 4:05:00 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sidoti's August Micro-Cap Virtual Conference

    Presentation Times and Weblinks Released for Over 50 Presenting CompaniesWednesday and Thursday, August 17-18, 2022NEW YORK, NY / ACCESSWIRE / August 16, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 17-18, 2022. The links can also be found at www.sidoticonference.com/events.Presentation AgendaWednesday, August 17th, 2022 (Day 1)*All Times EDT8:30-9:00Mativ Holdings, Inc. (MATV)Brenmiller Energy, Ltd. (BNRG)Sify Technologies Ltd (SIFY)9:15-9:45MISTRAS Group (MG)Bassett Furniture (BSET)Silvercrest Asset Management Group (SAMG)10:00-10:30Anebulo Pharmaceuticals (ANEB)*****

    8/16/22 3:00:00 PM ET
    $AIRI
    $ANEB
    $APRN
    Military/Government/Technical
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Update: Grove, Inc. to Present at Sidoti August Microcap Conference

    HENDERSON, NV , Aug. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Grove Inc. (GRVI) announced today that Allan Marshall, Chief Executive Officer, is scheduled to present virtually at the Sidoti & Company, August Virtual Microcap Conference on Wednesday, August 17, 2022 at 3:15 pm ET. The presentation can be accessed live at: https://sidoti.zoom.us/webinar/register/WN_FqCzxA3xTbOsMXr-Ml5X7Q Grove will also host virtual one-on-ones with investors throughout the conference.  To register for the presentation of a one-on-one meeting, visit https://www.sidoti.com/events/august-micro-cap-virtual-conference. Registration is free and you are not required to be a Sidoti & Company client. 

    8/10/22 10:56:39 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Financials

    Live finance-specific insights

    View All

    Grove, Inc. Announces Fiscal Year 2021 Audited Financial Results

    Revenues Reach $24.1 Million, a 250% Increase Over 2020 Net Earnings of $2.9 Million or $.25 Per Share HENDERSON, NV, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Grove, Inc. (NASDAQ:GRVI) ("Grove" or the "Company"), a global innovator in hemp, health, and wellness, today announced audited financial results for its fiscal year ended June 30, 2021 which surpassed preliminary results issued on June 28, 2021.   Investors are encouraged to read the Company's annual report on Form 10-K which was filed with the Securities and Exchange Commission (the "SEC"), contains additional information, and is posted at https://groveinc.io/ Financial Highlights $2

    9/29/21 8:00:00 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Grove Inc.

    SC 13G - GROVE, INC. (0001775194) (Subject)

    2/14/22 4:08:22 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Grove Inc.

    SC 13G - GROVE, INC. (0001775194) (Subject)

    2/14/22 4:07:48 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Grove Inc.

    SC 13G - GROVE, INC. (0001775194) (Subject)

    2/14/22 4:07:14 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care